

## Case study

### Courtesy of Mr. Robert Morley

Specialist Registrar in Podiatric Surgery, Derbyshire, UK

#### Clinical particulars

67-year-old male patient with type 2 diabetes presented with a 1 year history of a right foot ulcer and symptoms of infection with osteomyelitis caused by *Staphylococcus aureus*. Previous treatment involved 9 months I.V. antibiotics and regular re-dressing with no improvement. Most oral antibiotics were contraindicated due to a history of *Clostridium difficile*.

#### Treatment

After surgical debridement and thorough irrigation, **STIMULAN** was used to fill the resulting dead space. Gentamicin and vancomycin were used to treat the infection. A 3 day perioperative course of I.V. antibiotic therapy was administered based on a bone biopsy with no other antibiotics used post-operatively.

#### Outcome

5 weeks post-surgery the surgical wound and ulcer had healed and erythema and swelling had fully reduced. ESR and CRP were within normal limits and x-rays showed no deterioration. At 3 months the patient was mobilizing normally, free from infection and the **STIMULAN** had fully absorbed. Implantation of **STIMULAN** negated the need to perform a full forefoot amputation.



Presentation



17 days



3 months



3 months

For indications, contraindications, warnings and precautions see Instructions for Use. Concurrent use of locally administered antibiotics may affect setting time. This brochure may include the use of STIMULAN or techniques that go beyond the current clearance/approval granted by the relevant regulatory authority. Please contact your local representative for further information.

©2021 Biocomposites, STIMULAN, Bringing Calcium to Life, Power to Transform and DRy26 are trademarks/registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorized copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

Patents granted: GB2367552, EP 1204599 B1, US 6780391, EP 2594231 B1, US 8883063, CN ZL201210466117.X, GB2496710, EP 3058899 B1, US 10390954, US 10,588,748, CN ZL201610089710.5  
Patents pending: GB1502655.2, GB1704688.9, EP 18275044.8, US 15/933936, CN 108619579A